SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a dengue vaccine protect those with autoimmune conditions?
⭐️ VACCINE ⭐️ Recruiting nowThis study is testing a live attenuated dengue vaccine (Butantan-DV) in 477 people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) and in healthy volunteers. The goal is to see if the vaccine is safe and produces a strong immune response …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 29, 2026 15:03 UTC
-
Engineered immune cells take aim at lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage study is testing a new treatment called BZE2204 for people with three types of autoimmune diseases that have not responded to standard therapies: lupus, idiopathic inflammatory myopathies, and immune thrombocytopenia. The treatment uses a patient's own immune cel…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Cell Therapy Group Co.,Ltd • Aim: Disease control
Last updated May 01, 2026 15:43 UTC
-
New drug VIS171 tested for lupus, hair loss, and kidney disease
Disease control Recruiting nowThis early-stage trial tests a new drug called VIS171 in 30 adults with lupus, alopecia areata, or a kidney condition linked to the immune system. The main goal is to see if the drug is safe and tolerable when given as a shot under the skin. Participants will be followed for up t…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated May 01, 2026 15:42 UTC
-
New Immune-Targeting drug shows promise for tough autoimmune cases
Disease control Recruiting nowThis early-stage study tests the safety of a new drug called CC312 in 18 adults with autoimmune diseases like lupus, rheumatoid arthritis, and scleroderma that have not responded to standard treatments. CC312 works by helping the body's immune cells find and attack faulty B cells…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated May 01, 2026 15:42 UTC
-
New cell therapy aims to tame lupus and muscle inflammation
Disease control Recruiting nowThis early-stage study tests a new treatment called LUCAR-G79D in 38 adults with lupus or inflammatory myopathies that have not responded to standard therapies. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researchers will …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated May 01, 2026 15:40 UTC
-
Engineered immune cells take on lupus in first human test
Disease control Recruiting nowThis early-phase study tests a new treatment called CHT101 for people with lupus that has not responded to standard therapies. CHT101 uses specially engineered immune cells (CAR-T cells) to target and attack the faulty cells driving the disease. The study will enroll 15 participa…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated May 01, 2026 15:40 UTC
-
Lupus breakthrough? CAR T-Cell trial targets young patients
Disease control Recruiting nowThis study tests a new treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. The goal …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated May 01, 2026 15:40 UTC
-
Lupus patients get continued access to promising drug in new study
Disease control Recruiting nowThis study provides ongoing treatment with deucravacitinib for people with lupus (SLE or DLE/SCLE) who finished a prior related study. Up to 35 participants will continue the drug to help control their disease. The goal is to keep managing symptoms and prevent flares over the lon…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 01, 2026 15:39 UTC
-
New biologic combo shows promise for lupus kidney patients
Disease control Recruiting nowThis study compares two biologic drugs (belimumab and telitacicept) against standard treatment for people with active lupus nephritis, a serious kidney complication of lupus. About 50 participants will receive either a biologic plus steroids, standard therapy (mycophenolate mofet…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Engineered immune cells aim to tame childhood autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new treatment made from a child's own immune cells, engineered to target and calm overactive immune cells that cause severe rheumatic diseases like lupus. About 36 children aged 5 and older who have not responded to standard treatments will receive …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New pill aims to calm lupus skin flares in major trial
Disease control Recruiting nowThis study tests an experimental drug called enpatoran for people with lupus who have active skin rashes. About 202 participants will take either enpatoran or a placebo pill for 24 weeks, along with their usual treatments. The goal is to see if the drug can significantly reduce s…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
Could a single cell therapy tame lupus and other autoimmune diseases?
Disease control Recruiting nowThis early-stage trial tests a new treatment called FT819 for people with certain autoimmune diseases like lupus, vasculitis, myositis, and scleroderma. The treatment aims to target and control the immune cells that cause these diseases. The study will check if FT819 is safe and …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
New cell therapy aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in 18 adults with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard therapies. Participants receive a single infusion of these specially designed cells. The main goal is to che…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
New study tracks lupus drug anifrolumab in daily practice across 10+ countries
Disease control Recruiting nowThis study follows 200 adults with systemic lupus erythematosus (SLE) who are starting anifrolumab for the first time as part of their usual care. Researchers will track disease activity, skin symptoms, fatigue, and quality of life over time using standard medical assessments. Th…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
New lupus shot enters human testing – could it tame the disease?
Disease control Recruiting nowThis study tests an experimental injection called DB-2304 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and side effects, not to cure the disease. About 148 participants will be monitored closely. If safe, the drug may help control lup…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
Could umbilical cord stem cells tame lupus? new trial begins
Disease control Recruiting nowThis early-stage study tests a single injection of stem cells from donated umbilical cords for people with active lupus. Ten adults will receive the cells alongside their usual care. Researchers will check if the treatment is safe and if it helps reduce disease activity and prote…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: LiveKidney.Bio • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New heart test could spot lupus damage early in kids
Knowledge-focused Recruiting nowThis study looks at 60 children with lupus to find early signs of heart problems using non-invasive ultrasound techniques. Researchers will measure heart chamber size, pumping strength, and valve health. The goal is to identify children at higher risk of heart issues so they can …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:50 UTC
-
Massive lupus study aims to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is building a large database of medical information and biological samples from 3,500 people with lupus. Researchers will use this resource to study the genetic and immune system factors that drive the disease. The goal is to better understand lupus and help develop mo…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Lupus Research Alliance • Aim: Knowledge-focused
Last updated Apr 29, 2026 15:14 UTC